EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, China Shineway Pharmaceutical Group's enterprise value is $-291.2 Mil.
China Shineway Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $178.9 Mil. Therefore, China Shineway Pharmaceutical Group's EV-to-EBITDA for today is -1.63.
CSWYY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.82 Med: 0.61 Max: 14.07
Current: -1.82
During the past 13 years, the highest EV-to-EBITDA of China Shineway Pharmaceutical Group was 14.07. The lowest was -1.82. And the median was 0.61.
CSWYY's EV-to-EBITDA is ranked better than 99.46% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.94
vs CSWYY: -1.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
China Shineway Pharmaceutical Group (OTCPK:CSWYY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Shineway Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
China Shineway Pharmaceutical Group's share price for today is $19.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Shineway Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $3.534.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's EV-to-EBITDA falls into.
China Shineway Pharmaceutical Group's current Enterprise Value is $-291.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Shineway Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $178.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group (CSWYY) has a EV-to-EBITDA of -1.63 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Shineway Pharmaceutical Group. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #4 out of 739 companies in the Drug Manufacturers industry, placing it in the top 0.5%.
Is China Shineway Pharmaceutical Group's EV-to-EBITDA too high?
China Shineway Pharmaceutical Group's current EV-to-EBITDA is -1.63. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #4 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #4 out of 739 companies for EV-to-EBITDA. This places China Shineway Pharmaceutical Group in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.94, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Shineway Pharmaceutical Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current EV-to-EBITDA is -1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current EV-to-EBITDA of -1.63. The stock's GF Value™ is $16.74, compared to a current price of $19.25 — trading 15% above its estimated fair value. The current EV-to-EBITDA is -1.63. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current EV-to-EBITDA is -1.63 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 15% above its estimated GF Value™ of $16.74.
Key valuation signals for CSWYY:
EV-to-EBITDA: -1.63
GF Value™: $16.74 vs. price of $19.25 (15% above fair value)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
